Dual immunotherapy with neoadjuvant chemotherapy shows encouraging activity in ERBB2-
A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform.
Threaded Mode